spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Stem Cell Therapeutics 

 HSMN NewsFeed - 26 Jun 2024
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn(R) Clinical Trial
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 20 Jun 2024
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 23 Feb 2024
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 24 Oct 2023
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn(R) for the Treatment of ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 18 Oct 2023
BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 12 Jul 2023
BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 27 Mar 2023
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn(R) for the Treatment of ALS
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 27 Dec 2022
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 10 Nov 2022
BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS
Biopharmaceuticals Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 15 Sep 2022
BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn(R) Phase 2 Progressive MS Trial in Multiple Sclerosis Journal
Regenerative Medicine Neurology
 HSMN NewsFeed - 27 Dec 2021
FDA Authorizes Further NurOwn(R) Dosing Under Expanded Access Program
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 8 Nov 2021
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 24 May 2021
Stemedica Signs License Agreement with Pulthera, LLC for all Respiratory Indications including those related to COVID-19
Regenerative Medicine Licensing
 HSMN NewsFeed - 14 Dec 2020
BrainStorm Announces NurOwn(R) Expanded Access Program
Regenerative Medicine Neurology Product Launch
 HSMN NewsFeed - 23 Nov 2020
BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
Regenerative Medicine Neurology
 HSMN NewsFeed - 17 Nov 2020
BrainStorm Announces Topline Results from NurOwn(R) Phase 3 ALS Study
Regenerative Medicine Neurology
 HSMN NewsFeed - 24 Jun 2020
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
Regenerative Medicine Neurology
 HSMN NewsFeed - 27 May 2020
BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 28 Jun 2018
BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello
Regenerative Medicine Personnel
 HSMN NewsFeed - 5 Feb 2018
BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 17 Aug 2017
BlueRock Therapeutics Expands Toronto Presence with R&D and Manufacturing Hub, Appoints Key R&D Leadership
Regenerative Medicine Personnel
 HSMN NewsFeed - 28 Jan 2016
Cynata Receives Favourable Advice from UK Regulatory Authority
Regenerative Medicine Regulatory
 HSMN NewsFeed - 10 Mar 2014
Stem Cell Therapeutics Strengthens its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Jan 2014
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 Oct 2013
Stem Cell Therapeutics Receives U.S. Orphan Drug Designation for the Use of Tigecycline to Treat Acute Myeloid Leukemia
Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 17 Oct 2013
OncoMed Pharmaceuticals Appoints Michael Wyzga to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Mar 2013
Stem Cell Therapeutics Provides Corporate Update on Acquisitions and Financing
Regenerative Medicine Mergers & Acquisitions
 HSMN NewsFeed - 4 Feb 2013
Stem Cell Therapeutics Announces Agreement With Trillium Therapeutics Inc. for Merger
Regenerative Medicine Mergers & Acquisitions
 HSMN NewsFeed - 7 Dec 2010
Medistem Announces New Management Team
Regenerative Medicine Personnel
 HSMN NewsFeed - 17 Jun 2010
Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
Biopharmaceuticals Regenerative Medicine Oncology
 HSMN NewsFeed - 17 Jun 2010
OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
Biopharmaceuticals Regenerative Medicine Oncology
 HSMN NewsFeed - 2 Jun 2010
Alnylam Strengthens Management Team with New Key Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jul 2009
Stem Cell Therapeutics Corp. Receives Green Light to Begin Enrolling Patients in the India Phase IIb Acute Ischemic Stroke Trial
Regenerative Medicine Neurology
 HSMN NewsFeed - 7 Jul 2009
OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2008
Stem Cell Therapeutics Corp. Receives Letter From Health Canada and Verbal Request From FDA to Place a Clinical Hold on Its REGENESIS Phase IIb Stroke Trial in Canada and the US, Respectively
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 30 May 2008
Stem Cell Therapeutics Corp. Expands Executive Team by Appointing Thomas Franck as Vice President of Commercial Planning
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 23 Apr 2008
Stem Cell Therapeutics Corp. Receives "May Proceed" From FDA for Its Phase IIb Clinical Stroke Trial and IND
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 20 Feb 2008
Stem Cell Therapeutics Announces Favorable Results From the Phase IIa BETAS Stroke Trial
Regenerative Medicine Neurology
 HSMN NewsFeed - 11 Jul 2007
StemCyte Appoints Robert Dickey IV as Senior Vice President and Chief Financial Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 3 Apr 2007
NeoStem Announces Launch of Government Affairs Initiative
Regenerative Medicine
 HSMN NewsFeed - 15 Mar 2007
NeoStem Hires Experienced Marketing Executive Arlene Graime to Direct Government Affairs and Raise Nationwide Consumer Awareness
Regenerative Medicine Personnel
 HSMN NewsFeed - 6 Nov 2006
Elbit Medical Group Announces Receipt of a Special Protocol Assessment From the FDA to Gamida Cell's Stemex(R) Registration Study
Regenerative Medicine FDA
 HSMN NewsFeed - 2 Nov 2006
Gamida Cell's StemEx(R) Registration Study Receives Special Protocol Assessment from the FDA
Regenerative Medicine FDA
 HSMN NewsFeed - 26 Oct 2006
NeoStem, Inc. Appoints Julio C. Guerra, MD, ABP, as Director of Sales and Marketing
Regenerative Medicine Personnel
 HSMN NewsFeed - 11 May 2006
Stem Cell Therapeutics Corp. Announces Issuance of Second US Patent
Regenerative Medicine
Return to NewsFeed  

 Additional items found! 16

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 16 additional stories matching:
Stem Cell Therapeutics
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.